Terlivaz® (terlipressin) has been approved for IV injection. Terlivaz is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function.
- HRS involving rapid reduction in kidney function is an acute, life-threatening condition that occurs in people with advanced liver disease.
- Terlivaz is contraindicated:
- In patients experiencing hypoxia or worsening respiratory symptoms.
- In patients with ongoing coronary, peripheral, or mesenteric ischemia.
- Terlivaz is expected to be available in the S. in the coming weeks.
